Abhishek Gulati

US Patent:

20200368229, Nov 26, 2020

Filed:

Aug 2, 2017

Appl. No.:

15/667212

Inventors:

- North Chicago IL, US
Bo Fu - Lake Bluff IL, US
Abhishek Gulati - North Chicago IL, US
Jens Kort - Hawthorn Woods IL, US
Matthew Kosloski - Wilmette IL, US
Yang Lei - North Chicago IL, US
Chih-Wei Lin - Vernon Hills IL, US
Ran Liu - North Chicago IL, US
Federico Mensa - Rye Brook NY, US
Iok Chan Ng - Arlington Heights IL, US
David Pugatch - North Chicago IL, US
Nancy S. Shulman - North Chicago IL, US
Roger Trinh - Chicago IL, US
Rolando M. Viani - North Chicago IL, US
Stanley Wang - Buffalo Grove IL, US
Zhenzhen Zhang - North Chicago IL, US

Assignee:

AbbVie Inc. - North Chicago IL

International Classification:

A61K 31/4985
A61K 31/454

Abstract:

The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents to a subject with HCV infection, wherein the treatment lasts for 12 weeks and does not include administration of either interferon or ribavirin, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof.

US Patent:

20200330460, Oct 22, 2020

Filed:

Aug 30, 2018

Appl. No.:

16/643069

Inventors:

- North Chicago IL, US
Emily O. Dumas - LIbertyville IL, US
Bo Fu - Lake Bluff IL, US
Abhishek Gulati - Mundelein IL, US
Yiran Bonnie Hu - Libertyville IL, US
Jens Kort - Hawthorn Woods IL, US
Matthew Kosloski - Wilmette IL, US
Preethi Krishnan - Gurnee IL, US
Yang Lei - North Chicago IL, US
Chih-Wei Lin - Vernon Hills IL, US
Ran Liu - North Chicago IL, US
Frederico Mensa - Rye Brook NY, US
Iok Chan Ng - Arlington Heights IL, US
David Pugatch - San Jose CA, US
Susan Rhee - North Chicago IL, US
Nancy S. Shulman - Palto Alto CA, US
Roger Trinh - Chicago IL, US
Rolando M. Viani - North Chicago IL, US
Stanley Wang - Buffalo Grove IL, US
Zhenzhan Zhang - North Chicago IL, US

Assignee:

AbbVie Inc. - North Chicago IL

International Classification:

A61K 31/4985
A61K 31/454
A61K 31/7072
A61K 31/498

Abstract:

The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents to a subject with HCV infection, wherein the treatment lasts for 12 weeks and does not include administration of either interferon or ribavirin, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof.

US Patent:

20200222397, Jul 16, 2020

Filed:

Jul 20, 2018

Appl. No.:

16/635813

Inventors:

- North Chicago IL, US
Bo Fu - Lake Bluff WI, US
Abhishek Gulati - North Chicago IL, US
Jens Kort - Hawthorn Woods IL, US
Matthew Kosloski - Wilmette IL, US
Yang Lei - North Chicago IL, US
Chih-Wei Lin - Vernon Hills IL, US
Ran Liu - North Chicago IL, US
Federico Mensa - Rye Brook NY, US
Iok Chan Ng - Arlington Heights IL, US
David Pugatch - North Chicago IL, US
Nancy S. Shulman - North Chicago IL, US
Roger Trinh - Chicago IL, US
Rolando M. Viani - North Chicago IL, US
Stanley Wang - Buffalo Grove IL, US
Zhenzhen Zhang - North Chicago IL, US

Assignee:

AbbVie Inc. - North Chicago IL

International Classification:

A61K 31/4985
A61K 31/454
A61K 31/7072
A61K 31/498

Abstract:

The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 16 weeks, alternatively no more than 12 weeks, or alternatively no more than 8 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents to a subject with HCV infection, wherein the treatment lasts for 16, 12, or 8 weeks and does not include administration of either interferon or ribavirin, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof.

US Patent:

20170360783, Dec 21, 2017

Filed:

Sep 1, 2017

Appl. No.:

15/693963

Inventors:

- North Chicago IL, US
Emily O. Dumas - LIbertyville IL, US
Bo Fu - Lake Bluff IL, US
Abhishek Gulati - Mundelein IL, US
Yiran Bonnie Hu - Libertyville, TW
Jens Kort - Hawthorn Woods IL, US
Matthew Kosloski - Wilmette IL, US
Preethi Krishnan - Gurnee, IN
Yang Lei - North Chicago IL, US
Chih-Wei Lin - Vernon Hills IL, US
Ran Liu - North Chicago IL, US
Federico Mensa - Rye Brook NY, US
Iok Chan Ng - Arlington Heights IL, US
David Pugatch - San Jose CA, US
Susan Rhee - North Chicago IL, US
Nancy S. Shulman - Palo Alto CA, US
Roger Trinh - Chicago IL, US
Rolado M. Viani - North Chicago IL, US
Stanley Wang - Buffalo Grove IL, US
Zhenzhen Zhang - North Chicago IL, US

Assignee:

AbbVie Inc. - North Chicago IL

International Classification:

A61K 31/4985
A61K 31/454

Abstract:

The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 16 weeks, alternatively no more than 12 weeks, or alternatively no more than 8 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents to a subject with HCV infection, wherein the treatment lasts for 16, 12, or 8 weeks and does not include administration of either interferon or ribavirin, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof.